Demis Hassabis, chief of Google DeepMind, believes there's a 50% chance of achieving AGI within 5 years. AGI means ...

AI-powered drug company spun out of Google’s DeepMind says human trials are ‘very close’ After years of development, Isomorphic Labs says its AI-created drugs are nearly ready for human trials.

Among new hires, former Google Gemini engineering lead Amar Subramanya joined Microsoft AI as corporate vice-president.

Google DeepMind CEO Demis Hassabis heads Gemini and the company's AI push while gaining more power. Here's how he became ...

Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in ...

MSFT Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Isomorphic Labs is nearing human clinical trials for drugs developed using AI. Isomorphic helps pharma partners with their drug development programs while also working on its own internal drug ...

Researchers are urging developers to prioritize research into “chain-of-thought” processes, which provide a window into how ...

Discover how AI models from Google and OpenAI outshined human brilliance at the 2025 IMO, and the ethical debates that ...

Google has announced the consolidation of its formerly separate AI research labs — Google Brain and DeepMind — into a new unit named Google DeepMind. The new team will spearhead groundbreaking ...

As DeepMind explains, they trained their AI agents to behave the way some economists model human decision making. That is, selfish and always rational. "The research may enable us to better ...